# Gilead Sciences, Inc. – Consensus ‘buy’ rating and 5.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc-consensus-buy-rating-and-5-6-upside-potential/4121185466
- Published: 2025-01-31T12:47:03+00:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** which can be found using ticker (GILD) have now 25 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between $125.00 and $73.00 and has a mean target
at $100.96. Now with the previous closing price of $95.59 this is indicating there
is a potential upside of 5.6%. Also worth taking note is the 50 day moving average
now sits at $91.85 and the 200 day MA is $79.38. The total market capitalization
for the company now stands at 120.83B. The stock price is currently at: $96.95 USD

 The potential market cap would be $127,609,505,242 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 1077.22, revenue per share of $22.70
and a 11.96% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on:
